送交者: lijun 于 2006-4-09, 22:05:49:
回答: Thanks alot. 由 BerkeleyWolf 于 2006-4-09, 20:30:45:
It's a very famous drug. It was approved in US in 2000, which is targeting at Abl tyrosine kinase. Now it's in the development of second generation to overcome the resistance.
As far as I know, the costs for patients without insurance are very high. In China, most CML patients cannot afford to use it becuase it's only made by Novartis and no other pharmaceutical companies are able to make it because of the patent issue.